Biomerica Will Market Cancer Test in Japan
- Share via
Dow Jones
Biomerica Inc., a Newport Beach medical technology company, said Monday it will market its 10-minute prostate cancer test to hospitals and physicians in Japan through Nihon Schering, a unit of Schering AG. Financial terms were not disclosed.
Biomerica said last week that Japanese regulators approved the sale of its EZ-PSA test, which detects elevated levels of prostate-specific antigen, an early warning indicator of prostate cancer.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
